Tissue engineered myoblast sheets improved cardiac function sufficiently to discontinue LVAS in a patient with DCM: report of a case
Tissue engineered myoblast sheets improved cardiac function sufficiently to discontinue LVAS in a patient with DCM: report of a case
复制标题
DOI：
10.1007/s00595-011-0106-4
复制
发表时间：
2012-01-01
期刊：
影响因子：
2.5
通讯作者：
Okano, Teruo
中科院分区：
文献类型：
--
作者：
Sawa, Yoshiki;Miyagawa, Shigeru;Okano, Teruo
扩张型心肌病（DCM）是一种以进行性心力衰竭为特征的心肌疾病，是导致死亡和发病的主要原因。最近，终末期心力衰竭的细胞治疗已经出现。我们在此报告一位56岁男性接受自体成肌细胞片在温度反应培养皿中制造的移植。他的临床状况明显改善，没有任何心律失常，能够停止使用左心室辅助系统，避免心脏移植。这些发现表明，使用成肌细胞片的细胞疗法是治疗终末期DCM患者的一种有前途的新策略。这种方法可能是一种有效的替代心脏移植在不久的将来。
Dilated cardiomyopathy (DCM) is a heart muscle disease characterized by progressive heart failure, and is a leading cause of mortality and morbidity. Recently, cellular therapy for end-stage heart failure has been emerging. We herein report a 56-year-old male who received a transplant of autologous myoblast sheets manufactured in temperature-responsive culture dishes. His clinical condition improved markedly, leaving him without any arrhythmia and able to discontinue using a left ventricular assist system and avoid cardiac transplantation. These findings suggest that cellular therapy using myoblast sheets is a promising new strategy for treating patients with end-stage DCM. This method might be an effective alternative to heart transplantation in the near future.